Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3858279

Next Previous
Drug Profile

GSK 3858279

Alternative Names: GSK-3858279

Latest Information Update: 12 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Analgesics; Anti-inflammatories
  • Mechanism of Action Chemokine CCL17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain

Most Recent Events

  • 24 Apr 2025 GlaxoSmithKline terminates a phase II trial in Pain (In adults, In the elderly) in USA, Canada, China, France, Germany, Japan, South Korea, South Africa, Spain, and United Kingdom (unspecified route) based on the lack of efficacy at the interim data review (NCT05838755) (EudraCT2022-502313-28-00)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Pain(In the elderly, In volunteers, In adults) in Australia (SC)
  • 03 Dec 2024 GlaxoSmithKline terminates phase II trial in United Kingdom, Spain, South Africa, Mexico, South Korea, Japan, Germany, France, China, Canada, Australia, Argentina, USA (unspecified route) (NCT05838742) (EudraCT2022-502799-22-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top